{"id":"W4412634163","doi":"10.1177/17588359251357719","title":"Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University of Toronto; Dalhousie University; University of Calgary; Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre; BC Cancer Agency; Nova Scotia Health Authority; BC Cancer Foundation; Juravinski Cancer Centre","funders":"Eisai Canada; AstraZeneca Canada","keywords":"Medicine; Atezolizumab; Bevacizumab; Lenvatinib; Clinical endpoint; Oncology; Durvalumab; Internal medicine; Hepatocellular carcinoma; Embolization; Perioperative; Sorafenib; Clinical trial; Nivolumab; Surgery; Immunotherapy; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001871469,0.0002469156,0.00132826,0.0006411585,0.0001379277,0.0007301088,0.000349363,0.0003321324,0.001344771],"category_scores_gemma":[0.003119476,0.0001232456,0.001167192,0.0004408018,0.0001885519,0.0006700975,0.0002763278,0.0008119058,0.0001732213],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004845352,"about_ca_system_score_gemma":0.0005820142,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002965095,"about_ca_topic_score_gemma":0.001012264,"domain_scores_codex":[0.9991917,0.0004151091,0.000173085,0.00007526162,0.0001104602,0.00003439536],"domain_scores_gemma":[0.9984912,0.001030901,0.000285728,0.00002595163,0.000112935,0.00005327906],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003723162,0.0001419756,0.002224022,0.01768535,0.001585903,0.0001978936,0.00006790001,0.00057625,0.002024506,0.0008534415,0.004028799,0.9668908],"study_design_scores_gemma":[0.008203615,0.02849391,0.059293,0.05135735,0.02902738,0.009786457,0.0006796449,0.00292384,0.01222872,0.00620673,0.7916383,0.0001609904],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006308294,0.9915596,0.000133197,0.000509443,0.0001057732,0.0000188281,0.00003118551,0.000007768981,0.001325878],"genre_scores_gemma":[0.1479883,0.8478884,0.001161139,0.001364053,0.0005652896,0.000107034,0.0002028695,0.00001170942,0.0007111573],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001871469,"threshold_uncertainty_score":0.009897351,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04158528642405861,"score_gpt":0.3582130287363358,"score_spread":0.3166277423122772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}